The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
HanniganE.V., FreedmanR.S., RutledgeF.N.Adjuvant chemotherapy in early uterine sarcoma. Gynecol Oncol.1983; 15(1): 56–64.
2.
HanniganE.V., FreedmanR.S., ElderK.W., RutledgeF.N.Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol.1983; 15(2): 224–229.
3.
LopezM., Di LauroL., PapaldoP., PernoC.F.Alternating combination chemotherapy of advanced soft tissue sarcomas in adults. Am J Clin Oncol.1984; 7(5): 539–542.
4.
SlaytonR.E., ParkR.C., SilverbergS.G., ShingletonH., CreasmanW.T., BlessingJ.A.Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. Cancer.1985; 56(2): 243–248.
5.
van NagellJ.R.Jr, HansonM.B., DonaldsonE.S., GallionH.H.Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer.1986; 57(8): 1451–1454.
6.
WongL.C., NganH.Y., MaH.K.Primary treatment with vincristine, dactinomycin, and cyclophosphamide in nondysgerminomatous germ cell tumor of the ovary. Gynecol Oncol.1989; 34(2): 155–158.
7.
SchoenfeldD.A., RosenbaumC., HortonJ., WolterJ.M., FalksonG., DeContiR.C.A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer.1982; 50(12): 2757–2762.
8.
MaurerH.M., BeltangadyM., GehanE.A.The intergroup rhabdomyosarcoma study-I. A final report. Cancer.1988; 61(2): 209–220.
9.
MarinaN., FontanesiJ., KunL.Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer.1992; 70(10): 2568–2575.
10.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–745.
11.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
12.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines Antiemesis. V.3.2008. http://www.nccn.org. Accessed April 18, 2008.
13.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
16.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–457.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
19.
SmithT.J., KhatcheressianJ., LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
20.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology—Myeloid Growth Factors. V.1.2008. http://www.nccn.org. Accessed April 26, 2008.
21.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
22.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
23.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
24.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
